Ausakang: Subsidiary ASKC202 completes dosing of the first patient in Phase III clinical trial.

OuSaiKang announcement, the subsidiary Jiangsu OuSaiKang Pharmaceutical Co., Ltd.'s development of a first-in-class innovative drug ASKC202 in combination with erlotinib for the treatment of locally advanced or metastatic non-small cell lung cancer with MET amplification/overexpression following treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) has completed the first patient dosing in its registrational Phase III clinical study. ASKC202 is a novel oral cMET inhibitor developed by Jiangsu OuSaiKang Pharmaceutical Co., Ltd. with proprietary intellectual property rights, a new molecular entity, and significant activity, specifically for the treatment of advanced NSCLC patients with EGFR mutations and MET amplification/overexpression after progression on EGFR TKI therapy.